Skip to main
IFRX
IFRX logo

InflaRx (IFRX) Stock Forecast & Price Target

InflaRx (IFRX) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 7%
Sell 7%
Strong Sell 0%

Bulls say

InflaRx NV has received marketing authorization from the European Commission for Gohibic (vilobelimab) to treat adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS), demonstrating significant clinical efficacy with a 23.9% relative reduction in 28-day all-cause mortality compared to placebo. The treatment has shown a high rate of complete resolution of dT and has maintained a favorable safety profile across various doses, indicating its potential as a key therapeutic option in a critical health crisis. The company’s proprietary anti-C5a/C5aR technology underpins its innovative approach to treating inflammatory diseases, contributing to a solid foundation for future growth and development within the biopharmaceutical sector.

Bears say

InflaRx NV's stock outlook is negatively impacted by concerns regarding its dependence on clinical trial outcomes, as the maximum HiSCR rate for its treatment Gohibic is only marginally higher than that of the placebo, suggesting limited efficacy. Additionally, while the company is exploring partnership and distribution options in Europe, these moves are not projected to significantly alleviate cash burn rates, indicating ongoing financial strain. Overall, the modest clinical results coupled with sustained cash consumption heighten the risk profile of InflaRx's business model.

InflaRx (IFRX) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 7% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About InflaRx (IFRX) Forecast

Analysts have given InflaRx (IFRX) a Buy based on their latest research and market trends.

According to 14 analysts, InflaRx (IFRX) has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

InflaRx (IFRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.